Considering that SKOV3 and A2780 have a PIK3CA-activating mutation, however, our results provide strong evidence that p110β-targeted therapy could be useful for the treatment of chemoresistant cancer cells, even in the condition of PIK3CA-activating mutations, not only for the PTEN-deficient cancers. Here, PIK3CA is linked to cancer.